Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia

Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America
David HirschwerkSusan Condon

Abstract

We cared for a patient with methicillin-resistant Staphylococcus aureus bacteremia who experienced clinical failure with daptomycin. The failure was accompanied by progressive elevation of the daptomycin minimum inhibitory concentration during treatment. DNA fingerprinting confirmed that the minimum inhibitory concentration elevation occurred within the same strain of methicillin-resistant Staphylococcus aureus. This observation provides important new information to clinicians who adopt this promising drug for treatment of serious infections caused by methicillin-resistant Staphylococcus aureus.

References

May 17, 2001·Antimicrobial Agents and Chemotherapy·J A SilvermanT Li
Apr 4, 2003·The New England Journal of Medicine·Soju ChangUNKNOWN Vancomycin-Resistant Staphylococcus aureus Investigative Team
Apr 24, 2003·Antimicrobial Agents and Chemotherapy·George SakoulasClaudie Thauvin Eliopoulos
Feb 7, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Benjamin P HowdenM Lindsay Grayson
Mar 23, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Christopher F Carpenter, Henry F Chambers
Jul 27, 2004·Antimicrobial Agents and Chemotherapy·Kenneth H Rand, Herbert J Houck
Jan 14, 2005·Heart & Lung : the Journal of Critical Care·Sowjanya S MohanBurke A Cunha
Feb 12, 2005·The Journal of Antimicrobial Chemotherapy·Judith N SteenbergenFrancis P Tally
Apr 13, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A MangiliD H Hamer

❮ Previous
Next ❯

Citations

Jan 25, 2008·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M SharmaR Khatib
Dec 31, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S J van HalI B Gosbell
Aug 9, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Helen W Boucher, George Sakoulas
May 28, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·George Sakoulas, Robert C Moellering
Oct 10, 2008·The Journal of Antimicrobial Chemotherapy·Donald P Levine
Oct 10, 2008·The Journal of Antimicrobial Chemotherapy·R E Warren
Sep 18, 2009·The Journal of Antimicrobial Chemotherapy·Karen E BowkerAlasdair P MacGowan
Nov 17, 2011·The Journal of Antimicrobial Chemotherapy·F Kate Gould Working Party of the British Society for Antimicrobial Chemotherapy
Nov 29, 2007·The Pediatric Infectious Disease Journal·Monica I ArduraPablo J Sánchez
Mar 20, 2009·The Pediatric Infectious Disease Journal·Lara M JacobsonRavit Arav-Boger
Oct 19, 2012·Journal of Clinical Microbiology·Elizabeth L Palavecino, Jacqueline M Burnell
Jan 7, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Catherine LiuUNKNOWN Infectious Diseases Society of America
Dec 5, 2008·Expert Review of Anti-infective Therapy·Peter K Linden
Nov 28, 2007·Expert Review of Anti-infective Therapy·Cindy A Loffler, Conan Macdougall
Jun 30, 2006·Expert Opinion on Pharmacotherapy·Su Young LeeDavid P Nicolau
Nov 2, 2006·Current Medical Research and Opinion·Javier Garau
Jul 17, 2007·The Journal of Infection·David A EnochJ Andreas Karas
Jun 28, 2007·Pharmacotherapy·Thomas P Lodise, Peggy S McKinnon
Jul 6, 2015·International Journal of Antimicrobial Agents·Stefania StefaniGiovanni Pacini
Feb 19, 2010·Expert Opinion on Pharmacotherapy·Christos Kosmidis, Donald P Levine
Sep 26, 2009·The Lancet Infectious Diseases·Pamela A MoiseGeorge Sakoulas
Oct 18, 2007·Pharmacology·Robert SauermannChristian Joukhadar
Oct 24, 2017·The Journal of Antimicrobial Chemotherapy·Mohsen HeidaryMehdi Goudarzi
Mar 16, 2007·Expert Opinion on Emerging Drugs·Emma J Bishop, Benjamin P Howden
Feb 20, 2009·Current Opinion in Otolaryngology & Head and Neck Surgery

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.